Zalifrelimab clinical trials
Also written AGEN1884.
- studies test it
- 8
- open now
- 0
- in phase 3
- 0
- first study started
- 2016
How each study uses zalifrelimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2017 (2)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 2 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 2
Agenus Inc. (4) · ImmunoGenesis (1) · University of Colorado, Denver (1) · UroGen Pharma Ltd. (1) · The University of Texas Health Science Center at San Antonio (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test zalifrelimab.
- Apr 2027Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue SarcomasPhase 2 · University of Colorado, Denver
- Oct 2027A Study of Evofosfamide in Combination With Zalifrelimab and BalstilimabPhase 1/2 · ImmunoGenesis
Studies
Open first, then newest update. How each study uses zalifrelimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Study of Evofosfamide in Combination With Zalifrelimab and BalstilimabActive, not recruitingPhase 1/2ImmunoGenesisNCT06782555Written as Zalifrelimab
- A Study of Zalifrelimab and Balstilimab for Treatment of Participants With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical)CompletedPhase 1/2Agenus Inc.NCT03495882Written as Zalifrelimab
- Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue SarcomasActive, not recruitingPhase 2University of Colorado, DenverNCT04028063Written as Zalifrelimab
- A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)CompletedPhase 1UroGen Pharma Ltd.NCT05375903Written as UGN-301
- AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent TherapyCompletedPhase 1/2Agenus Inc.NCT02694822Written as Zalifrelimab
- AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder CancerTerminatedPhase 2The University of Texas Health Science Center at San AntonioNCT04430036Written as AGEN1884
- A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical CancerWithdrawnPhase 2Agenus Inc.NCT05033132Written as Balstilimab + Zalifrelimab
- Study of AGEN1884 With Pembrolizumab in 1L NSCLCTerminatedPhase 2Agenus Inc.NCT03411473Written as AGEN1884 in combination with pembrolizumab
Given beside what is tested · 4 — zalifrelimab is usual care or a partner of the new treatment
- rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMGRecruitingPhase 1Ann & Robert H Lurie Children's Hospital of ChicagoNCT04943848Written as Zalifrelimab
- RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical CancerTerminatedPhase 2Agenus Inc.NCT03894215Written as AGEN1884
- Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic CancerActive, not recruitingPhase 1/2Nelum CorpNCT04827953Written as Zalifrelimab
- AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable AngiosarcomaWithdrawnPhase 2Agenus Inc.NCT04607200Written as AGEN1884
Codes
What other systems call zalifrelimab · ClinicalTrials.gg INT016555
- UNII (FDA) FE7L22H028ZALIFRELIMABOne source FDA
- NCI Thesaurus C126113ZalifrelimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | FE7L22H028 | ZALIFRELIMAB | One source FDA |
| NCI Thesaurus | C126113 | Zalifrelimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.